Analyzing Moolec Science (MLEC) and Its Rivals

Moolec Science (NASDAQ:MLEC) is one of 495 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Moolec Science to similar companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.5% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 19.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Moolec Science and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.35
Moolec Science Competitors	$211.82 million	-$15.63 million	125.19

Moolec Science’s peers have higher revenue, but lower earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Moolec Science and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	963	2820	7059	106	2.58

Moolec Science presently has a consensus target price of $6.00, suggesting a potential upside of 589.73%. As a group, “Biotechnology” companies have a potential upside of 28.90%. Given Moolec Science’s stronger consensus rating and higher possible upside, analysts plainly believe Moolec Science is more favorable than its peers.

Profitability

This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,267.69%	-105.83%	-28.54%

Risk & Volatility

Moolec Science has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.

Summary

Moolec Science beats its peers on 7 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.